Abstract. Gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors. It is possible to carry out three consecutive lines of target therapy against metastatic GISTs: imatinib as first-line, sunitinib as second line and regorafenib as third line. Almost all metastatic GISTs eventually develop resistance to imatinib and sunitinib, resulting in fatal disease progression. Regorafenib is effective after the failure of imatinib and sunitinib. Some patients stop treatment due to sunitinib related toxicity. Regorafenib can be used as the second line therapy of metastatic GISTs in case of sunitinib intolerance.
Key words: gastrointestinal stromal tumors (GISTs), target therapy, regorafenib.
I.A. Koroleva, A.M. Koroleva
Medical University «REAVIZ», Samara
Samara State Medical University, Samara
Koroleva I.A. ― D. Med. Sc., oncologist of Multidisciplinary clinic of Medical University «REAVIZ»
227 Chapaevskaya Str., Samara, Russian Federation, 443001, tel.: (846) 321-21-21, +7-902-338-94-94, e-mail: firstname.lastname@example.org